Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The trades have taken place between February 18, 2025 and February 21, 2025. • JPMorgan Chase (NYSE:JPM) disclosed a series of transactions this week.
Bristol Myers Squibb GC to Retire After 33 years With Drugmaker
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make decisions quickly and to be accountable for those decisions."
Bristol-Myers Squibb (BMY) Receives a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.
Bristol Myers Squibb Lights the Way to Treasury Innovation
For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with Celgene in one of the biggest acquisitions in pharmaceutical history, the company’s treasury team needed to regroup.
Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid long-term pick despite short-term risks.
7BMY : Bristol-Myers Squibb Unusual Options Activity
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $60.0 for Bristol-Myers Squibb, spanning the last three months.
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Nations Financial Group Inc. IA ADV Sells 708 Shares of Bristol-Myers Squibb (NYSE:BMY)
Nations Financial Group Inc. IA ADV lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 10.3% in ...
FiercePharma2d
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Hosted on MSN1d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
stocknews17h
3 Precision Medicine Stocks That Could Transform Healthcare
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
Pharmabiz4h
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
GlobalData on MSN5d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...